首页 | 本学科首页   官方微博 | 高级检索  
     

syndecan-1在胃黏膜癌变不同阶段组织中的表达及意义
引用本文:Xi YX,Song X,Chen J,Chen HX,Peng TS,Lin HL,Chen MH. syndecan-1在胃黏膜癌变不同阶段组织中的表达及意义[J]. 中华肿瘤杂志, 2007, 29(3): 193-196
作者姓名:Xi YX  Song X  Chen J  Chen HX  Peng TS  Lin HL  Chen MH
作者单位:1. 518112,深圳市布吉人民医院胃镜室
2. 510080,广州,中山大学附属第一医院消化科
3. 510080,广州,中山大学附属第一医院病理科
基金项目:基金项目:中国博士后科学基金资助项目(2004035181),广东省自然科学基金资助项目(4009350),国家自然科学基金资助项目(30671904、30670949)
摘    要:目的探讨黏附分子syndecan-1在胃癌癌变各阶段的表达及其在胃癌发生和转移中的意义。方法选取56例慢性浅表性胃炎、50例慢性萎缩性胃炎、59例肠化生、61例中重度异型增生、55例无淋巴结转移胃癌、57例有淋巴结转移胃癌的病理组织蜡块,采用免疫组化ABC法检测syndecan-1在胃黏膜癌变各阶段组织中的表达。结果慢性浅表性胃炎组、慢性萎缩性胃炎组、肠化生组、中重度异型增生组、无淋巴结转移胃癌组、有淋巴结转移胃癌组syndecan-1阳性表达率分别为96.43%、98.00%、100.00%、91.80%、45.45%和24.56%。慢性浅表性胃炎组、慢性萎缩性胃炎组、肠化生组3组间差异无统计学意义(P>0.05);肠化生组与中重度异型增生组、中重度异型增生组与无淋巴结转移胃癌组、无淋巴结转移胃癌组与有淋巴结转移胃癌组之间差异均有统计学意义(P均< 0.05)。低分化胃癌组syndecan-1阳性表达率为24.62%,明显低于中、高分化胃癌组(42.55%)。结论黏附分子syndecan-1表达下调与胃癌的发生有关,并可能进一步促进胃癌转移。

关 键 词:syndecan-1  免疫组织化学  胃肿瘤  肿瘤转移
修稿时间:2006-01-18

Expression of syndecan-1 at different stages in the course of gastric carcinoma and its significance
Xi Yin-xue,Song Xin,Chen Jie,Chen Hui-xin,Peng Ting-sheng,Lin Han-liang,Chen Min-hu. Expression of syndecan-1 at different stages in the course of gastric carcinoma and its significance[J]. Chinese Journal of Oncology, 2007, 29(3): 193-196
Authors:Xi Yin-xue  Song Xin  Chen Jie  Chen Hui-xin  Peng Ting-sheng  Lin Han-liang  Chen Min-hu
Affiliation:Department of Gastroenterology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China
Abstract:Objective To investigate the expression of syndecan-1 protein at different stages in the course of gastric carcinoma and its significance in carcinogenesis and metastasis. Methods There were 56 cases of chronic gastritis, 50 cases of chronic atrophic gastritis, 59 cases of intestinal metaplasia, 61 cases of displasia, and 112 cases of gastric carcinoma. Among the carcinoma cases, 55 were without and 57 with lymph node metastases. All paraffin-embedded tissue samples were assessed by immunohistochemistry. Results The syndecan-1 positive rate was 96.43% (54/56) in gastritis, 98.00% (49/50) in chronic atrophic gastritis, 100.00% (59/59) in intestinal metaplasia, 91.80% (56/61) in displasia, 45.45% (25/55) in gastric carcinoma without, and 24. 56% ( 14/57) in gastric carcinoma with lymph node metastases. There was no significant difference among chronic gastritis, chronic atrophic gastritis and intestinal metaplasia( P > 0. 05 ). There was a significant difference between displasia group and gastric carcinoma group (P<0.05) , as well as between gastric carcinoma with and without lymph node metastases. There was a significant difference among well, moderately and poorly differentiated carcinoma groups. Conclusion A decreasing expression of syedecan-1 in the development of gastric carcinoma is related with gastric carcinogenesis, and it may further promote metastasis of gastric carcinoma.
Keywords:syndecan-1  Immunohistochemistry  Stomach neoplasms  Neoplasm metastasis
本文献已被 CNKI 维普 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号